Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genome editing company Editas Medicine closes $43mm Series A round

Executive Summary

Flagship Ventures, Polaris Partners, and Third Rock Ventures led a $43mm Series A financing for genome editing start-up Editas Medicine Inc. Partners Innovation Fund also participated. A principal from Polaris will be Editas’ interim president and a Third Rock Partner partner will act as interim CSO. Representatives from Polaris, Third Rock, and Flagship joined Editas’ board.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies